Table 2.
Summary of adjusted effects of deprivation on clinical outcomes and use of treatments in patients with cystic fibrosis in the UK
| Patients younger than 18 years | Patients aged 18 years to <40 years | |
|---|---|---|
| Clinical outcomes* | ||
| FEV1 (percentage points [95% CI]) | −4·12 (−5·01 to −3·19) | −1·6 (−4·41 to 1·25) |
| Weight-for-age (SD score [95% CI]) | −0·28 (−0·38 to −0·18) | −0·31 (−0·46 to −0·16) |
| Height-for-age (SD score [95% CI]) | −0·31 (−0·40 to −0·21) | −0·31 (−0·43 to −0·19) |
| BMI-for-age (SD score [95% CI]) | −0·13 (−0·22 to −0·04) | −0·12 (−0·25 to 0·01) |
| Pseudomonas aeruginosa colonisation (OR [95% CI]) | 1·89 (1·34 to 2·66) | 1·78 (1·26 to 2·51) |
| Treatments | ||
| Any intravenous treatment (OR [95% CI])† | 2·52 (1·92 to 3·17) | 1·89 (1·51 to 2·38) |
| Total intravenous days per year (% change [95% CI])† | 15·9 (8·2 to 24) | 10·6 (2·5 to 19·2) |
| Supplemental feeding (OR [95% CI])‡ | 1·78 (1·42 to 2·2) | 2·38 (1·69 to 3·36) |
| DNase treatment (OR [95% CI])† | 0·40 (0·21 to 0·72) | 0·37 (0·26 to 0·52) |
| Use of inhaled antibiotics (OR [95% CI])† | 0·66 (0·47 to 0·93) | 0·40 (0·31 to 0·5) |
All estimates compare the most deprived quintile to the least deprived (reference) quintile.
*
The outcomes are from separate longitudinal models adjusted for time trends, sex, genotype, screening status, and ethnic origin.
†
Adjusted for time trends, sex, genotype, screening status, (FEV1), and Pseudomonas aeruginosa colonisation status.
‡
Adjusted for time trends, sex, genotype, screening status, and body mass index (BMI) SD score.